CL2020001781A1 - Un péptido de nudo de cistina (ckp) de origen no natural que se une a la proteína relacionada con el receptor de lipoproteína de baja densidad 6 (lrp6) humana. (divisional solicitud 201800668) - Google Patents

Un péptido de nudo de cistina (ckp) de origen no natural que se une a la proteína relacionada con el receptor de lipoproteína de baja densidad 6 (lrp6) humana. (divisional solicitud 201800668)

Info

Publication number
CL2020001781A1
CL2020001781A1 CL2020001781A CL2020001781A CL2020001781A1 CL 2020001781 A1 CL2020001781 A1 CL 2020001781A1 CL 2020001781 A CL2020001781 A CL 2020001781A CL 2020001781 A CL2020001781 A CL 2020001781A CL 2020001781 A1 CL2020001781 A1 CL 2020001781A1
Authority
CL
Chile
Prior art keywords
naturally occurring
lrp6
density lipoprotein
related protein
ckp
Prior art date
Application number
CL2020001781A
Other languages
English (en)
Inventor
Rami Hannoush
Harini Kaluarachchi
Aaron NILE
Cameron Noland
Yingnan Zhang
Lijuan Zhou
Xinxin Gao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2020001781A1 publication Critical patent/CL2020001781A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/63—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan péptidos de nudo de cistina (CKP) de origen no natural que se unen a VEGFA. Además, se proporcionan métodos para utilizar los CKP de origen no natural que se unen a VEGF-A, incluidas composiciones y métodos de diagnóstico y terapéuticos. También se proporcionan CKP de origen no natural que se unen a la proteína relacionada con el receptor de lipoproteína de baja densidad 6 (LRP6).
CL2020001781A 2015-09-15 2020-07-02 Un péptido de nudo de cistina (ckp) de origen no natural que se une a la proteína relacionada con el receptor de lipoproteína de baja densidad 6 (lrp6) humana. (divisional solicitud 201800668) CL2020001781A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562219063P 2015-09-15 2015-09-15

Publications (1)

Publication Number Publication Date
CL2020001781A1 true CL2020001781A1 (es) 2020-10-23

Family

ID=57068206

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018000668A CL2018000668A1 (es) 2015-09-15 2018-03-13 Plataforma de andamio con nudo de tierra.
CL2020001781A CL2020001781A1 (es) 2015-09-15 2020-07-02 Un péptido de nudo de cistina (ckp) de origen no natural que se une a la proteína relacionada con el receptor de lipoproteína de baja densidad 6 (lrp6) humana. (divisional solicitud 201800668)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018000668A CL2018000668A1 (es) 2015-09-15 2018-03-13 Plataforma de andamio con nudo de tierra.

Country Status (23)

Country Link
US (7) US10428125B2 (es)
EP (1) EP3350215A1 (es)
JP (2) JP7166916B2 (es)
KR (1) KR20180052718A (es)
CN (3) CN114591422A (es)
AR (1) AR106032A1 (es)
AU (2) AU2016323445B2 (es)
BR (1) BR112018002263A2 (es)
CA (1) CA2996006A1 (es)
CL (2) CL2018000668A1 (es)
CO (1) CO2018002510A2 (es)
CR (1) CR20180169A (es)
HK (1) HK1253318A1 (es)
IL (2) IL257399B (es)
MA (1) MA42828A (es)
MX (1) MX2018002922A (es)
MY (1) MY190552A (es)
PE (1) PE20181293A1 (es)
PH (1) PH12018500577A1 (es)
RU (1) RU2770384C2 (es)
TW (1) TWI799366B (es)
UA (1) UA125505C2 (es)
WO (1) WO2017049009A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
EP4164693A1 (en) 2020-06-11 2023-04-19 Genentech, Inc. Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US918814A (en) 1907-10-30 1909-04-20 Handy Mfg Company Funnel.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
CZ20003099A3 (cs) 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1268544A2 (en) 2000-03-31 2003-01-02 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
EP1290169A2 (en) 2000-06-01 2003-03-12 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
EP2316394B1 (en) 2001-06-12 2016-11-23 The Johns Hopkins University Reservoir device for intraocular drug delivery
AU2002340080A1 (en) 2001-10-03 2003-04-14 Regeneron Pharmaceuticals, Inc. Anti-angiogenic peptides
GB0130738D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Protein
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
PT1844337E (pt) 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20090305994A1 (en) 2005-06-29 2009-12-10 D Andrea Lucas Domenico Compounds Modulating Vegf Receptor and Uses Thereof
EP1929073A4 (en) * 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
TW200732347A (en) 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
WO2007131050A2 (en) 2006-05-02 2007-11-15 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
WO2008070479A2 (en) 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
CN101835492B (zh) 2007-08-21 2012-11-21 德克萨斯州立大学董事会 用于制药应用的热动力学混合
PL2274008T3 (pl) 2008-03-27 2014-07-31 Zymogenetics Inc Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2010048588A2 (en) * 2008-10-23 2010-04-29 Massachusetts Institute Of Technology Directed engagement of activating fc receptors
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
EP2391419B1 (en) 2009-01-29 2019-06-12 ForSight Vision4, Inc. Posterior segment drug delivery
US8778888B2 (en) 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
US20110207653A1 (en) 2009-12-21 2011-08-25 Adrian Raiche Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent
JP2013515741A (ja) 2009-12-23 2013-05-09 サイヴィーダ ユーエス，インコーポレイテッド 持続放出性送達デバイス
US8339139B2 (en) * 2010-01-29 2012-12-25 Infineon Technologies Ag System and method for testing a circuit
EP3604549A1 (en) 2010-11-08 2020-02-05 The Board of Trustees of the Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
UA112769C2 (uk) * 2011-02-18 2016-10-25 Ендо Фармасьютікалз Інк. Аміноінданові сполуки і їх застосування при лікуванні болю
US9187553B2 (en) 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
EP2890389A1 (en) 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
GB201218278D0 (en) * 2012-10-11 2012-11-28 Cyclogenix Ltd Translocating peptide
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺

Also Published As

Publication number Publication date
WO2017049009A1 (en) 2017-03-23
US20170129927A1 (en) 2017-05-11
JP2022130481A (ja) 2022-09-06
AU2021204400B2 (en) 2023-02-02
CL2018000668A1 (es) 2018-07-20
EP3350215A1 (en) 2018-07-25
AU2016323445B2 (en) 2021-04-01
TW201717993A (zh) 2017-06-01
JP2018533912A (ja) 2018-11-22
US20200325187A1 (en) 2020-10-15
HK1253318A1 (zh) 2019-06-14
US20200140498A1 (en) 2020-05-07
IL294568A (en) 2022-09-01
BR112018002263A2 (pt) 2018-09-18
MX2018002922A (es) 2018-06-07
CN114805528A (zh) 2022-07-29
CN114591422A (zh) 2022-06-07
TWI799366B (zh) 2023-04-21
IL257399A (en) 2018-04-30
US11155586B2 (en) 2021-10-26
IL257399B (en) 2022-08-01
JP7166916B2 (ja) 2022-11-08
CO2018002510A2 (es) 2018-05-31
PH12018500577A1 (en) 2018-10-15
CN108026162A (zh) 2018-05-11
US20230174596A1 (en) 2023-06-08
AR106032A1 (es) 2017-12-06
RU2018113442A3 (es) 2020-02-17
US11078243B2 (en) 2021-08-03
CA2996006A1 (en) 2017-03-23
MY190552A (en) 2022-04-27
UA125505C2 (uk) 2022-04-13
US10696721B2 (en) 2020-06-30
US10428125B2 (en) 2019-10-01
KR20180052718A (ko) 2018-05-18
RU2018113442A (ru) 2019-10-16
US20180291069A1 (en) 2018-10-11
AU2016323445A1 (en) 2018-03-01
US20200231636A1 (en) 2020-07-23
WO2017049009A8 (en) 2018-02-22
CN108026162B (zh) 2022-04-05
AU2021204400A1 (en) 2021-07-22
US11407794B2 (en) 2022-08-09
PE20181293A1 (es) 2018-08-07
CR20180169A (es) 2018-04-24
MA42828A (fr) 2018-07-25
RU2770384C2 (ru) 2022-04-15
US20200115424A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
CL2020001781A1 (es) Un péptido de nudo de cistina (ckp) de origen no natural que se une a la proteína relacionada con el receptor de lipoproteína de baja densidad 6 (lrp6) humana. (divisional solicitud 201800668)
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
CO2019010524A2 (es) Plataforma de identificación de péptidos inmunogénicos basada en población
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
BR112016012358A2 (pt) peptídios terapêuticos
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
AR093788A1 (es) Inmunoterapia con agentes de enlace
SV2017005486A (es) Anticuerpos a tau y usos de los mismos
EA201991207A1 (ru) Новые агонисты tnfr и их применение
EA201792245A1 (ru) Биоконъюгаты и их применения
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
CL2019003430A1 (es) Tratamiento conjunto antineoplásico.
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
CO2019006073A2 (es) Estructura cristalina de gremlina 1 y anticuerpo inhibidor
PE20160031A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y metodos de uso
AR093620A1 (es) Anticuerpos bmp-6
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
UY36663A (es) Anticuerpos anti-ap2 y agentes de unión al antígeno para tratar trastornos metabólicos
MX2020004561A (es) Anticuerpos biespecificos que se unen a alk-1 y bmpr-2.
ECSP18046820A (es) Polipéptidos que inhiben cd40l
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas